Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005031 · ClinicalTrials.gov registry record · Phase 2
Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer
A Phase 2 study of Endometrial Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00005031: Completed Phase 2 study of Endometrial Cancer, sponsored by Gynecologic Oncology Group.
NCT00005031 is a Phase 2 study of Endometrial Cancer that has completed, run by Gynecologic Oncology Group. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005031, a Phase 2 study of Endometrial Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have persistent or recurrent refractory endometrial cancer.
Conditions Studied
Interventions
- DRUG irofulven
Study Locations (20)
California
- Community Hospital of Los Gatos - Los Gatos
- Chao Family Comprehensive Cancer Center - Orange
Illinois
- Rush-Presbyterian-St. Luke's Medical Center - Chicago
- University of Chicago Cancer Research Center - Chicago
Massachusetts
- Tufts University School of Medicine - Boston
- University of Massachusetts Memorial Medical Center - Worcester
Missouri
- Ellis Fischel Cancer Center - Columbia
- Washington University School of Medicine - St Louis
New York
- Cancer Center of Albany Medical Center - Albany
- University of Rochester Cancer Center - Rochester
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
District of Columbia
- Walter Reed Army Medical Center - Washington D.C.
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-08 |
| Phase | Phase 2 |
What the finished NCT00005031 record still lists
NCT00005031 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which irofulven is the first listed.
NCT00005031 names 20 study sites across 15 states, led by California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00005031 about?
NCT00005031 is a clinical study titled "Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have persistent or recurrent refractory endometrial cancer.
What is the current status of trial NCT00005031?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-08.
What conditions does trial NCT00005031 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT00005031?
The interventions under investigation include: irofulven (DRUG).
Who is sponsoring clinical trial NCT00005031?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005031 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia